---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-26-000057"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:26:33.786512+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio Q1 net product revenue $44.2M, up 168% YoY; ANKTIVA approvals expand; cash $381M

## Summary
- Q1 2026 net product revenue $44.2M, up 168% YoY ($16.5M) and 15% sequentially from Q4 2025 ($38.3M).
- ANKTIVA unit sales up 168% YoY; approved in 5 jurisdictions covering ~34 countries, including first Asia approval in Macau.
- Cash and marketable securities $380.9M as of March 31, 2026, up from $242.8M at Dec 31, 2025.
- Pivotal BCG-naïve CIS trial fully enrolled; sBLA submission on track for 2026.
- GAAP net loss $632.8M driven by non-cash fair value changes; adjusted net loss $86.2M vs $82.7M.

## SEC filing metadata
- accession: 0001326110-26-000057
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000057/0001326110-26-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000057/ibrx-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-26-000057
- JSON: https://secwatch.observer/filing/0001326110-26-000057.json
- Plain text: https://secwatch.observer/filing/0001326110-26-000057.txt

## Source-grounded claims
- claim_id: f3caa065651a7927426015e549f5f4ed7b3b5ca2
  claim: ImmunityBio, Inc. reported the three months ended March 31, 2026 results: revenue $44.2 million.
  evidence_excerpt: 9 – Financial Statements and Exhibits. --- EX-99.1 (EX-99.1) --- ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million • Q1 2026 Revenue Growth with Continued Strong
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000057/0001326110-26-000057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.